Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Symptoms and General Pathology

Carcinoma

Prostatic Neoplasms

Disease Progression

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

All Drugs and Chemicals

Androgens

Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy

Cabozantinib

Aldo Roccaro

Alfredo Berruti

Multiparametric assesment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents: a phase II study

This is a monocentric, single arm, prospective clinical trial designed to obtain explorative information about the effect of Cabozantinib on bone in prostate cancer patients with bone metastatic castration resistant disease, previously treated with two taxanes and at least one next generation hormonal agent.

Activity of bone metastatic disease will be assessed by WB-DW-MRI, while changes in bone metabolism will be studied through DXA scan and soluble biomarkers

Monocentrici Study. The patients are treated in one arm

Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib

Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib Upon Progression to Chemotherapy and Next Generation Hormonal Agents: a Phase II Study

Proportion of patients attaining a partial or complete response to therapy on bone metastases by means of WB-DW MRI.

Proportion of patients attaining a partial or complete response to therapy on bone metastases by means of bone scan.

Change in bone pain and quality of life through the administration of validated questionnaires.

Time from treatment initiation and disease progression or death from any cause.

Time from treatment initiation and death from any cause.

Proprtion of SRE defined as the occurrence of one among: spinal cord compression, pathologic fracture, necessity for radiation to bone or surgery to bone.

Director of the Medical Oncology Unit

Pain

Central Nervous System Depressants

Anti-Arrhythmia Agents

Channel Blockers

Anti-Inflammatory Agents

Antirheumatic Agents

Analgesics

Anesthetics

Lidocaine

Anesthetics, Local

Diclofenac

Sodium Channel Blockers

Diuretics, Potassium Sparing

Anti-Inflammatory Agents, Non-Steroidal

Analgesics, Non-Narcotic

Cyclooxygenase Inhibitors

Enzyme Inhibitors

Used as local aneaethetic as a part of institutional prostate biopsy protocol

Diclofenac suppository plus lidocaine gel

Lidocaine gel only

Naveed Haroon, MBBS

Transrectal ultrasound guided biopsy of prostate (TRUS-Bx) is widely used as accepted mode of investigation for prostate cancer in current urology practice. It is considered a minor procedure, which most of the patients tolerate, however 20% of patients refuse to undergo the redo procedure without any analgesia or anesthesia but on the other hand, some authors reveal that 65 to 90% of patients report pain ranging from mild to severe in intensity. Diclofenac is a local and systemic anti-inflammatory drug and it reduces local mediators involved in local pain.The purpose of this study is to find out the role of rectal administration of diclofenac suppositories as an adjunct to 2% xylocaine gel in alleviating intra and post procedural pain in prostatic biopsy with adequately calculated sample size and excluding the patients with contraindication to procedure or diclofenac administration as these were the shortcomings of previous studies.

Efficacy of Diclofenac Suppository for Pain Control in Ultrasound Guided Biopsy of Prostate

Diclofenac Suppository As a Preemptive Analgesia in Ultrasound Guided Biopsy of Prostate: Randomized Controlled Trial

Aga Khan University

Resident

Respiratory Tract (Lung and Bronchial) Diseases

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

Skin and Connective Tissue Diseases

Digestive System Diseases

Ear, Nose, and Throat Diseases

Gland and Hormone Related Diseases

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Multiple Myeloma

Neoplasms, Plasma Cell

Breast Neoplasms

Esophageal Neoplasms

Carcinoma, Hepatocellular

Cholangiocarcinoma

Ascites

Vulvar Neoplasms

Carcinoma, Renal Cell

Hypersensitivity

Carcinoma, Ductal

Carcinoma, Neuroendocrine

Pleural Effusion, Malignant

Pleural Effusion

Mesothelioma

Mesothelioma, Malignant

Anus Neoplasms

Carcinoma, Small Cell

Laryngeal Diseases

Urinary Bladder Neoplasms

Small Cell Lung Carcinoma

Carcinoma, Ovarian Epithelial

Thymoma

Thymus Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Breast Diseases

Skin Diseases

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Adenocarcinoma

Adenoma

Neoplasms, Mesothelial

Pleural Neoplasms

Carcinoma, Bronchogenic

Bronchial Neoplasms

Pleural Diseases

Head and Neck Neoplasms

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Kidney Neoplasms

Urologic Neoplasms

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Esophageal Diseases

Rectal Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Intestinal Diseases

Anus Diseases

Rectal Diseases

Urinary Bladder Diseases

Genital Neoplasms, Female

Vulvar Diseases

Genital Diseases, Female

Ovarian Neoplasms

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Endocrine System Diseases

Gonadal Disorders

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Lymphatic Diseases

Esophageal Cancer

Bile Duct Cancer

Diagnosis of any kind of carcinoma with a malignant fluid (pleural effusion or ascites) where drainage is clinically indicated as part of SOC, and a new course of treatment is upcoming.

Diagnosis of any kind of carcinoma where a needle biopsy or tissue resection is clinically indicated as part of SOC, and a new course of treatment is upcoming.

Diagnosis of relapsed multiple myeloma where bone marrow biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.

Diagnosis of acute myelogenous leukemia where a blood draw or bone marrow biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.

Diagnosis of Stage IV Triple Negative Breast Cancer where a needle biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.

Diagnosis of any cancer where a blood draw is clinically indicated as part of SOC, a new course of treatment is upcoming, and checkpoint inhibitor therapy being considered for next line of treatment.

Mark Stevens, Ph.D.

Robert Kimmerling, Ph.D.

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

The best overall response to therapy over 24 months will be captured for correlation with test outcomes.

Travera Inc

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib	NCT05265988	Carcinoma Prost...	Cabozantinib	-	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Efficacy of Diclofenac Suppository for Pain Control in Ultrasound Guided Biopsy of Prostate	NCT01939743	Carcinoma Prost...	Diclofenac supp... Lidocaine gel o...	51 Years - 70 Years	Aga Khan University
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs	NCT04985357	Stage III Breas... Stage IV Breast... Stage III Lung ... Stage IV Lung C... AML Multiple Myelom... Carcinoma Carcinoma, Panc... Carcinoma of Lu... Carcinoma, Non-... Carcinoma Breas... Carcinoma Prost... Carcinoma, Hepa... Carcinoma, Rena... Carcinoma, Neur... Carcinoma, Smal... Carcinoma, Ovar... Carcinoma Bladd... Carcinoma of Es... Carcinoma Cervi... Carcinoma, Thym... Carcinoma, Duct... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of Un... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Malignant Pleur... Malignant Ascit... Mesothelioma Cholangiocarcin...		18 Years -	Travera Inc
Efficacy of Diclofenac Suppository for Pain Control in Ultrasound Guided Biopsy of Prostate	NCT01939743	Carcinoma Prost...	Diclofenac supp... Lidocaine gel o...	51 Years - 70 Years	Aga Khan University

Spots Global Cancer Trial Database for carcinoma prostate